Important pharmacy news and late-breaking industry information updated daily.

The tax overhaul bill being shaped into its final form by Senate and House Republicans is all but certain to cut tax credits designed to encourage development of orphan drugs meant to treat rare diseases afflicting limited numbers of patients.

Dozens of cities, counties and school districts across the country have quietly found a solution to soaring drug prices they say protects their budgets and saves workers money. They are helping their employees buy medicines from pharmacies in Canada and overseas, where prices are up to 80% cheaper.

DEA's Los Angeles Field Division recently announced Operation Faux Pharmacy, a multi-pronged initiative aimed at attacking the opioid epidemic by targeting rogue pharmacies throughout southern California, Hawaii, and Nevada.

FDA has approved semaglutide (Ozempic—Novo Nordisk) as an adjunct to diet and exercise for the treatment of type 2 diabetes in adults. The drug, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, was approved in 0.5-mg and 1.0-mg doses, to be administered once a week with a dedicated prefilled pen device.

The merger of CVS Health and Aetna would combine one of the country's biggest pharmacies with one of its largest health insurers. Executives at the firms say it will create a world where patients will get the "human touch," and that getting high-quality, low-cost medical care will be as close as your community pharmacy.

CVS has agreed to buy Aetna for about $69 billion, in a deal that would reshape the American health care industry by bringing a big provider of pharmacy services and a large insurer under one roof. As part of the deal, CVS plans to use its nearly 10,000 pharmacy locations to provide consumers with more local care options.

FDA approved on Thursday buprenorphine extended-release (Sublocade—Indivior), the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adults who have initiated treatment with a transmucosal buprenorphine-containing product.

Project IMPACT: Diabetes Prevention will expand access for at-risk adults in underserved communities

JAPhA study: All it takes is adding the Patient Health Questionnaire 9 to diabetes education

Alex Azar, the Trump administration's nominee to become the next HHS secretary, testified Wednesday that prescription drug prices are too high and that the federal government has a role in trying to make medicine more affordable for consumers.